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sImpact of Routine Completion Angiography on the Results of Primary
Carotid Endarterectomy: A Prospective Study in a Teaching Hospital
Ricco J.-B., Régnault de la Mothe G., Fujita S., Page O., Valagier A.,
Marchand C. Eur J Vasc Endovasc Surg 2011;41:579-88.
Objective: To assess the usefulness of completion angiography in the
prevention of stroke, carotid occlusion and residual stenosis after primary
carotid endarterectomy (CEA) in the setting of a teaching hospital.
Material and Methods: From January 1995 to August 2009, 1055
consecutive patients having 1179 CEAs were entered in a prospective study
excluding patients with severe renal insufficiency, allergy to contrast media
and patients with repeat CEA or carotid bypass. In this cohort, 552 patients
(52.3%) were asymptomatic, 318 (30.2%) had a transient ischaemic attack
(TIA) and 185 (17.5%) had a stroke. Routine completion angiography was
obtained in all 1055 patients. The decision to perform a surgical revision was
decided for any of the following defects: (1) a residual stenosis of more than
50% of the internal carotid artery (ICA) or common carotid artery (CCA)
and of more than 70% of the external carotid artery (ECA), (2) any flap and
(3) any intraluminal-filling defect. A postoperative duplex scan was obtained
within a week after surgery and thereafter on a yearly basis. Median fol-
low-up was 7 years.
Results: CEA was performed by a senior surgeon as first operator in
812 cases (69%) and by a trainee, with a scrubbed senior surgeon, in 367
cases (31%). Completion angiography revealed significant defects in 72 cases
(6.1%) warranting revision for ECA flap (n 30), thrombus in contact with
the patch (n  7), distal ICA flap or stenosis (n  20) and CCA flap or
residual plaque (n  15).
Logistic regression analysis showed that total length of the carotid
plaque 6 cm (p  0.02, Odds ratio: 2.31; 95% confidence interval (CI)
(1.21–3.72)), eversion endarterectomy of the ECA (p  0.01, Odds ratio
3.41; 95%CI (2.10–5.94)) and trainee as first operator (p 0.02, Odds ratio
2.42; 95%CI (1.81–4.23)) were independent predictors of operative defects
seen on completion angiography. No complication in relation to carotid
catheterisation or injection of contrast media occurred in this series.
The 30-day combined stroke and death rate was 1.5%, comparable
between senior surgeons and trainees (p  0.60). There was no significant
difference in the combined stroke and death rate observed in patients with
normal completion angiography (1.4%) compared with that of the patients
with a defect corrected (2.8%) (p  0.28, Odds ratio: 0.67; 95%CI (0.22–
2.09)). But there was an increased incidence of postoperative TIA in the
group with revision (p  0.001, odds ratio: 5.8, 95%CI: 1.8–18.9).
At 7 years, the freedom rate from50% carotid restenosis or occlusion
was 87.5 6.7% in patients with normal completion angiography and 92
5.4% in patients, who undergo a surgical revision.
Conclusion: In a single centre, CEA with routine completion angiog-
raphy resulted in good perioperative outcome. Plaque length, technique for
external carotid artery (ECA) endarterectomy and trainee as first operator
were independent predictors of operative defects seen on completion an-
giography.
Stroke after Cardiac Surgery and its Association with Asymptomatic
Carotid Disease: An Updated Systematic Review and Meta-analysis
Naylor A.R., Bown M.J. Eur J Vasc Endovasc Surg 2011;41:607-24.
Objectives: (i) Prevalence of stroke in neurologically symptomatic/
asymptomatic patients with unilateral/bilateral carotid disease (including
occlusion) undergoing cardiac surgery without prophylactic carotid endar-
terectomy (CEA) or carotid stenting (CAS). (ii) Prevalence of stroke in
asymptomatic patients with unilateral/bilateral carotid disease (excluding
occlusion) who underwent isolated cardiac surgery. (iii) Prevalence of stroke
in the hemisphere ipsilateral to a non-operated asymptomatic stenosis in
patients with severe bilateral carotid disease undergoing a synchronous
unilateral CEA  cardiac procedure.
Methods: Systematic Review and meta-analysis.
Results: Cardiac surgery patients with a symptomatic/asymptomatic
50–99% stenosis or occlusion incurred a 7.4% stroke risk (95%CI 4.8–9.9),
increasing to 9.1% (95%CI 4.8–16) in those with 80–99% stenoses or
occlusion. After excluding patients with a history of stroke/TIA and those
with isolated/bilateral occlusions, the stroke risk fell to 3.8% (95%CI 2.0–
4.8) in patients with asymptomatic 50–99% stenoses and 2.0% in those with
70–99% stenoses (95%CI 1.0–5.7). The prevalence of ipsilateral stroke in
patients with a unilateral, asymptomatic 50–99% stenosis was 2.0% (1.0–
3.8), while the risk of any stroke was only 2.9% (2%–5.7%). These risks did s
1450ot increase with stenosis severity (70–99%, 80–99%). Patients with bilat-
ral, asymptomatic 50–99% stenoses or a 50–99% stenosis  contralateral
cclusion incurred a 6.5% stroke risk following cardiac surgery, while the risk
f death/stroke was 9.1% (3.8%–20.6%). Patients with bilateral 80–99%
tenoses undergoing a unilateral synchronous cardiac/carotid revascularisa-
ion incurred a 5.7% risk of stroke in the hemisphere ipsilateral to the
on-operated, contralateral stenosis.
Conclusions: There is no compelling evidence supporting a role for
rophylactic CEA/CAS in cardiac surgery patients with unilateral asymp-
omatic carotid disease. Prophylactic CEA/CAS might still be considered in
atients with severe, bilateral asymptomatic carotid disease, but such a
trategy would only benefit 1–2% of all cardiac surgery patients.
pen or Endovascular Repair of Aortoenteric Fistulas? A Multicentre
omparative Study
akkos S.K., Antoniadis P.N., Klonaris C.N., Papazoglou K.O., Giannoukas
.D., Matsagkas M.I., Kotsis T., Dervisis K., Gerasimidis T., Tsolakis I.A.,
iapis C.D. Eur J Vasc Endovasc Surg 2011;41:625-34.
Objectives To compare aortoenteric fistula (AEF) outcome after en-
ovascular (EV-AEFR) or open repair (O-AEFR).
Design Multicentre retrospective comparative study.
Materials/Methods 25 patients with AEF (24 secondary, 23 males,
edian age 75 years) after aortic surgery (median four years). Preoperative
epsis was evident in 19 cases. Eight patients were managed with EV-AEFR
nd 17 with O-AEFR.
Results The two groups were comparable in preoperative characteris-
ics. In-hospital mortality after EV-AEFR was lower compared to O-AEFR
0% and 35%, respectively, p  0.13). Similarly, morbidity after EV-AEFR
as lower compared to O-AEFR (25% and 77%, respectively, p  0.028).
here was a trend for worse recurrence-free, sepsis-free, re-operation-free
nd AEF-related death-free rates after EV-AEFR, while the early survival
dvantage of EV-AEFR was lost after two years and the overall long-term
urvival rates (perioperative mortality included) of the two groups were
imilar. Preoperative sepsis had no effect on recurrence and sepsis-free rates
p  0.94 and p  0.92, respectively), but it was associated with worse two
ear overall survival (24% vs 50%, p  0.32). On multivariate analysis, the
umber of symptoms (two vs one) at presentation was the single predictor of
orse re-operation rates, AEF-related and overall survival.
Conclusions EV-AEFR was associated with no postoperative mortality
n this study and can achieve satisfactory short and long-term results,
omparable to O-AEFR. Further trials should focus on the role of EV-AEFR
n patients at high risk for O-AEFR, due to shock or co-morbidities, or as a
ridging procedure.
piral Vein Reconstruction of the Infected Abdominal Aorta Using
he Greater Saphenous Vein: Preliminary Results of the Tilburg
xperience
an Zitteren M., van der Steenhoven T.J., Burger D.H.C., van Berge
enegouwen D.P., Heyligers J.M.M., Vriens P.W.H.E. Eur J Vasc Endo-
asc Surg 2011;41:637-46.
Objectives: The aim of this study was to evaluate patients, who
nderwent spiral vein reconstruction of the abdominal aorta to repair
nfected aneurysms or replace infected aortic grafts.
Methods: All spiral vein reconstructions between March 2005 and
ay 2010 because of vascular infections of the abdominal aorta were
etrospectively included. Diagnosis was determined by clinical examination,
aboratory results, computed tomography (CT) and positron emission to-
ography (PET) scan and microbiological tests. Spiral vein reconstruction
onsisted of harvesting the greater saphenous vein (GSV) and construction
nto a spiral graft, aortic reconstruction and a transmesenteric omen-
umplasty. Primary outcomes were survival and limb salvage. Secondary
utcomes included technical, clinical and ongoing success, re-infection,
ngoing infection and patency.
Results: All five patients survived surgery, and there were no in-
ospital deaths. Survival and limb salvage were 100% after median follow-up
f 13 months (6–67 months). Further, technical, clinical and continuing
uccess was 100%. There were no re-infections or ongoing infections.Conclusions: Spiral vein reconstruction using the GSV showed good
hort-term survival and limb salvage. It, therefore, might be considered as an
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Volume 53, Number 5 Abstracts 1451attractive treatment method for vascular infections of the abdominal aorta.
Still, more follow-up is needed to evaluate long-term results.
Pharmacological Interventions to Attenuate the Expansion of Abdom-
inal Aortic Aneurysm (AAA) – A Systematic Review
Bergqvist D. Eur J Vasc Endovasc Surg 2011;41:663-7.
Introduction: Is it possible by pharmacological methods to attenuate
the expansion rate of abdominal aortic aneurysms?
Method: An Internet-based systematic literature search was performed
to identify published reports on pharmacological methods to influence
aneurysmal expansion rate.
Results: Of an original 450 articles, 22 remained to review: they
included 15 cohort studies with 12,321 patients and seven randomised
clinical trials (RCTs) with 1546 patients. Most studies are performed with-
out a pre-study sample size calculation. There is no consistent pattern of
pharmacological influence on expansion rate, but statins, non-steroidal
anti-inflammatory drugs (NSAIDs) and macrolides should be further eval-
uated.
Conclusion: Properly designed RCTs are needed before conclusions
can be drawn on the possibility to pharmacologically attenuate aneurysmal
expansion and prevent rupture.
The Scandinavian Propaten® Trial – 1-Year Patency of PTFE Vascular
Prostheses with Heparin-Bonded Luminal Surfaces Compared to Or-
dinary Pure PTFE Vascular Prostheses – A Randomised Clinical Con-
trolled Multi-centre Trial
Lindholt J.S., Gottschalksen B., Johannesen N., Dueholm D., Ravn H.,
Christensen E.D., Viddal B., Flørenes T., Pedersen G., Rasmussen M.,
Carstensen M., Grøndal N., Fasting H. Eur J Vasc Endovasc Surg 2011;41:
668-73.
Objective: To compare 1-year potencies’ of heparin-bonded PTFE
[(Hb-PTFE) (Propaten®)] grafts with those of ordinary polytetraflouroeth-
ylene (PTFE) grafts in a blinded, randomised, clinically controlled, multi-
centre study.
Materials and methods: Eleven Scandinavian centres enrolled 569
patients with chronic functional or critical lower limb ischaemia who were
scheduled to undergo femoro–femoral bypass or femoro–poplitaeal bypass.
The patients were randomised 1:1 stratified by centre. Patency was assessed
by duplex ultrasound scanning. A total of 546 patients (96%) completed the
study with adequate follow-up.
Results: Perioperative bleeding was, on average, 370 ml with PTFE
grafts and 399 ml with Heparin-bonded PTFE grafts (p  0.32).
Overall, primary patency after 1 year was 86.4% for Hb-PTFE grafts
and 79.9% for PTFE grafts (OR 0.627, 95% CI: 0.398; 0.989, p 0.043).
Secondary patency was 88% in Hb-PTFE grafts and 81% in PTFE grafts
(OR  0.569 (0.353; 0.917, p  0.020)).
Subgroup analyses revealed that significant reduction in risk (50%) was
observed when Hb-PTFE was used for femoro–poplitaeal bypass (OR 
0.515 (0.281; 0.944, p  0.030)), and a significant reduction in risk (50%)
was observed with Hb-PTFE in cases with critical ischaemia (OR  0.490
(0.249; 0.962, p  0.036)).
Conclusion: The Hb-PTFE graft significantly reduced the overall riskReaders can access EJVES articles at http://intl.eive-year Results of a Randomised Clinical Trial of Endovenous Laser
blation of the Great Saphenous Vein with and without Ligation of
he Saphenofemoral Junction
isselhoff B.C.V.M., der Kinderen D.J., Kelder J.C., Moll F.L. Eur J Vasc
ndovasc Surg 2011;41:685-90.
Objective: To evaluate whether ligation of the saphenofemoral junc-
ion (SFL) improves the results of endovenous laser ablation (EVLA) of the
reat saphenous vein (GSV) in a 5-year randomised clinical trial (RCT).
Methods: Forty-three symptomatic patients (86 limbs) with bilateral
ncompetent GSVs were randomised so that one limb underwent EVLA
ithout SFL and the other limb underwent EVLA with SFL. Eleven patients
ere lost to follow-up and two patients died, leaving 30 patients (60 limbs)
or analysis. Duplex-confirmed groin varicose vein recurrence and venous
linical severity score (VCSS) were investigated at 6, 12, 24 and 60 months
fter treatment.
Results: Five-year life table analysis showed freedom from groin vari-
ose vein recurrence in 79% of limbs (95% confidence interval (CI); 67–92%)
n the EVLA without SFL group and in 65% of limbs (95%; CI; 51–82) in
he EVLA with SFL group (P  0.36). Groin varicose vein recurrence was
ue to neo-vascularisation (0%), re-canalisation (9%) and incompetent trib-
taries in 14% in the EVLA without SFL group, and to neo-vascularisation
33%), re-canalisation (0%) and incompetent tributaries (0%) in the EVLA
ith SFL group. The VCSS improved significantly and was comparable in
oth groups.
Conclusion: The rate of varicose vein recurrence was similar in both
tudy groups. There was less neo-vascularisation in the EVLA without SFL
roup, but more incompetent tributaries and early re-canalisation at 5-year
ollow-up than in the EVLA with SFL group.
Registration number: ISRCTN60300873 (http://www.clinical-
rials.com).
ndovenous Laser Ablation (EVLA) to Treat Recurrent Varicose Veins
heivacumar N.S., Gough M.J. Eur J Vasc Endovasc Surg 2011;41:691-6.
Objectives: This cohort study assesses the effectiveness and safety of
ndovenous laser ablation (EVLA) in the management of recurrent varicose
eins (RVVS).
Method: 104 limbs (95 patients) undergoing EVLA for RVVS were
rouped according to pattern of reflux. For patients with recurrent SFJ/
reat saphenous vein (GSV) (Group GR) and SPJ/small saphenous vein
SSV) (Group SR) varicosities ablation rates and QoL (Aberdeen Varicose
ein Severity Scores (AVVSS)) were compared with those for age/sex
atched patients undergoing EVLA for primary GSV/SSV dependent
aricose veins (Groups GP and SP).
Results: In patients with RVVS the axial vein was ablated in 102/104
98%) limbs whilst 2 GSVs (group GR) partially recanalised by 3 months
GSV ablated in 49/51 (96%) limbs versus 50/51 (98%) limbs in GP [p 
.2]). Improvements in AVVSS at 3 months (median GR: 14.2 (inter-
uartile range (IQR) 10.2–18.9) to 3.2(1.2–6.4), p  0.001; GP: median
5.9(IQR 11.4–22.7) to 3.8(1.1–5.6), p  0.001, Mann–Whitney u-test)
ere similar (78% versus 76%, p  0.23). The SSV was ablated in 24/24
imbs in groups SR and SP and the % improvement in AVVSS was 83%
median 14.4 (IQR 8.2–19.4) to 2.4 (1.9–4.6), p 0.001, Mann–Whitney
-test) and 84% (median 13.8 (IQR 6.3–17.5) to 2.2 (1.2–5.1), p 0.001)
espectively (p 0.33). These improvements persisted at 1 year follow-up. A
urther 29 limbs with isolated anterior accessory great saphenous vein
AAGSV) or segmental GSV/SSV reflux were successfully ablated. Compli-
ation rates for primary and RVVS were similar.of primary graft failure by 37%. Risk reduction was 50% in femoro–poplitaeal
bypass cases and in cases with critical ischaemia.
Conclusions: EVLA is a safe and effective option for the treatment of
RVVS and could be a preferred option for suitable patients.lsevierhealth.com/journals/ejvs/default.cfm
